IRIS
AMODIO, Nicola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.335
AS - Asia 781
EU - Europa 469
SA - Sud America 198
Continente sconosciuto - Info sul continente non disponibili 81
AF - Africa 42
OC - Oceania 3
Totale 2.909
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.250
SG - Singapore 253
IT - Italia 248
VN - Vietnam 158
CN - Cina 146
BR - Brasile 135
HK - Hong Kong 54
BD - Bangladesh 53
DE - Germania 45
FR - Francia 41
CA - Canada 31
AR - Argentina 23
AT - Austria 23
GB - Regno Unito 22
UA - Ucraina 16
FI - Finlandia 14
IQ - Iraq 14
IN - India 13
KR - Corea 13
MX - Messico 12
CO - Colombia 9
SN - Senegal 9
NL - Olanda 8
RU - Federazione Russa 8
TR - Turchia 8
ZA - Sudafrica 8
DZ - Algeria 7
EC - Ecuador 7
GT - Guatemala 7
ID - Indonesia 7
JM - Giamaica 7
PK - Pakistan 7
SE - Svezia 7
CL - Cile 6
PL - Polonia 6
ES - Italia 5
NI - Nicaragua 5
PY - Paraguay 5
SA - Arabia Saudita 5
TT - Trinidad e Tobago 5
UZ - Uzbekistan 5
VE - Venezuela 5
EG - Egitto 4
HN - Honduras 4
NP - Nepal 4
PH - Filippine 4
RO - Romania 4
TH - Thailandia 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
BA - Bosnia-Erzegovina 3
BE - Belgio 3
BG - Bulgaria 3
EE - Estonia 3
IL - Israele 3
JP - Giappone 3
KG - Kirghizistan 3
MA - Marocco 3
PE - Perù 3
SV - El Salvador 3
TN - Tunisia 3
AU - Australia 2
BN - Brunei Darussalam 2
BO - Bolivia 2
CH - Svizzera 2
CR - Costa Rica 2
GP - Guadalupe 2
JO - Giordania 2
KZ - Kazakistan 2
MY - Malesia 2
OM - Oman 2
PA - Panama 2
PR - Porto Rico 2
RS - Serbia 2
SC - Seychelles 2
TG - Togo 2
TW - Taiwan 2
UY - Uruguay 2
AO - Angola 1
BB - Barbados 1
BH - Bahrain 1
BW - Botswana 1
BY - Bielorussia 1
BZ - Belize 1
CW - ???statistics.table.value.countryCode.CW??? 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
EU - Europa 1
GA - Gabon 1
GE - Georgia 1
GY - Guiana 1
IE - Irlanda 1
KH - Cambogia 1
KW - Kuwait 1
LB - Libano 1
LT - Lituania 1
NG - Nigeria 1
PF - Polinesia Francese 1
QA - Qatar 1
SI - Slovenia 1
Totale 2.829
Salva come PNG Salva come JPEG
Città #
Dallas 226
Council Bluffs 187
Ashburn 134
San Jose 122
Singapore 118
Hong Kong 51
Ho Chi Minh City 47
Hanoi 46
Beijing 41
Chandler 35
Milan 33
The Dalles 30
New York 28
Chicago 21
Lauterbourg 21
Los Angeles 20
Santa Clara 19
Longmont 16
Rome 16
Boardman 14
Florence 14
Helsinki 14
Phoenix 14
Vienna 14
Miano 13
Seoul 13
Da Nang 11
Rende 11
Munich 10
São Paulo 10
Dakar 9
Hefei 9
Montreal 8
Shanghai 8
Turin 8
Guangzhou 7
Haiphong 7
Naples 7
San Mateo 7
Atlanta 6
Baghdad 6
Buenos Aires 6
Frankfurt am Main 6
Secaucus 6
São José do Rio Preto 6
Toronto 6
Brescia 5
Guatemala City 5
Houston 5
Jacksonville 5
Managua 5
Medellín 5
Mexico City 5
North Bergen 5
Rio de Janeiro 5
San Antonio 5
Tashkent 5
Warsaw 5
Bari 4
Biên Hòa 4
Bremen 4
Buffalo 4
Catania 4
Denver 4
Duhok 4
Elk Grove Village 4
Falkenstein 4
Goiânia 4
Irvine 4
Kingston 4
Lawrence 4
Portsmouth 4
Riyadh 4
Seattle 4
Tianjin 4
Acerra 3
Brasília 3
Brooklyn 3
Brussels 3
Caracas 3
Charlotte 3
Dearborn 3
Fortaleza 3
Genoa 3
Greenville 3
Izmir 3
Las Vegas 3
London 3
Mauá 3
Miami 3
Mosul 3
Myrtle Beach 3
Newark 3
Noida 3
Ogden 3
Omaha 3
Orem 3
Philadelphia 3
Port of Spain 3
Porto Alegre 3
Totale 1.664
Salva come PNG Salva come JPEG
Nome #
Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options? 197
Mitochondrial Determinants of Anti-Cancer Drug-Induced Cardiotoxicity 160
Vaccination in Multiple Myeloma: Challenges and Strategies 155
First evidence on the novel hypothalamic peptide Phoenixin-14 as cardiac modulator and cardioprotective in normal and obese rats 154
Current Status and Future Perspectives on Therapeutic Potential of Apigenin: Focus on Metabolic-Syndrome-Dependent Organ Dysfunction 142
Dissecting the Biological Relevance and Clinical Impact of lncRNA MIAT in Multiple Myeloma 139
Targeting the MARCH5-MFN2 axis to enhance mitochondrial fusion and sensitize multiple myeloma cells to venetoclax 134
Mitochondrial fission factor drives an actionable metabolic vulnerability in multiple myeloma 125
Epigenetic regulation of mitochondrial quality control genes in multiple myeloma: A sequenom massarray pilot investigation on hmcls 116
A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients 92
GPER1 Activation Exerts Anti-Tumor Activity in Multiple Myeloma 89
Rilzabrutinib for the Treatment of Immune Thrombocytopenia 89
Maintenance therapy after ASCT in newly diagnosed multiple myeloma patients: single agent versus combination drugs 89
Discovery of a Promising Hydroxyamino-Piperidine HDAC6 Inhibitor via Integrated Virtual Screening and Experimental Validation in Multiple Myeloma 87
Treatment-Free Remission in Chronic Myeloid Leukemia: Revisiting the "W" Questions 74
Clinical Utility of Frailty Scoring in Elderly Acute Myeloid Leukemia Patients Treated With Venetoclax and Hypomethylating Agents 64
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real‐World Study 60
Real‐World Evaluation of Oral Decitabine/Cedazuridine in Elderly Patients With Acute Myeloid Leukemia 47
Clonal haematopoiesis in chronic lymphocytic leukaemia: Biology, inflammaging and clinical implications in the era of targeted therapy 46
Real-World Safety and Effectiveness of Zanubrutinib versus Ibrutinib in CLL: The CLL-ZANU2024 Italian Cohort 45
OPA1 as a Cancer Target: Molecular Mechanisms, Structural Insights, and Strategies for Drug Development 45
Beyond PD‐1: Mechanisms of Resistance to Checkpoint Blockade in Classical Hodgkin Lymphoma and Next‐Generation Immune Strategies 39
The Non-Coding RNA Journal Club: Highlights on Recent Papers-14 38
Ph‐Negative Acute Lymphoblastic Leukemia in the Older Adults: Biology, Therapeutic Strategies and Unmet Needs 36
Targeting Mitochondrial Vulnerabilities in Chronic Myeloid Leukemia: From Pathobiology to Novel Therapeutic Opportunities 36
Management of Primary Refractory Diffuse Large B‐Cell Lymphoma in Patients Unsuitable for CAR T‐Cell Therapy 36
Harnessing the novel safeguarding role of Selenoprotein T in age-related myocardial left and right decline through the ferroptosis-mitochondrial axis 35
Comparative efficacy of different therapeutic approaches in treatment naïve FLT3-mutated AML eligible for intensive chemotherapy: a Bayesian network meta-analysis of randomized trials 35
Targeting the Menin– KMT2A Axis in Acute Leukemia: From Epigenetic Dependency to Clinical Translation 34
Relapse Despite MRD Negativity in Multiple Myeloma: Toward Integrated Risk Prediction 33
Elranatamab in Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Emerging Perspectives 32
Reshaping multiple myeloma treatment: recent breakthroughs 31
Targeting Ikaros and Aiolos: Next‐Generation Cereblon E3 Ligase Modulators in MM 29
Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies 27
Exploiting ALK inhibition in anaplastic large cell lymphoma: Biological rationale and therapeutic integration 26
Frontline Therapy in Diffuse Large B‐Cell Lymphoma: Evolving Standards, Biological Insights, and Future Directions 24
First‐Line Treatment of IGHV ‐Unmutated Chronic Lymphocytic Leukemia: A Network Meta‐Analysis of Targeted and Chemoimmunotherapy Regimens 23
Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies 22
From Time‐Limited Therapy to Treatment‐Free Observation: The Evolving Role of MRD in CLL Management 20
High-dose ruxolitinib (25 mg twice daily) in myelofibrosis: feasibility, safety, and long-term treatment exposure in a real-world cohort 18
The Gut Microbiota in Hematologic Malignancies: Mechanisms, Clinical Associations, and Translational Opportunities 18
Gut Microbiota and Acute Myeloid Leukemia: State of the Art, Clinical Signals, and Translational Opportunities 18
Bispecific Antibodies for Acute Myeloid Leukemia: From Bone Marrow Immune Niche to Clinical Translation 17
DRP1-mediated mitochondrial fragmentation is a druggable vulnerability in multiple myeloma 16
Rethinking On‐Target Off‐Tumor Toxicity as a Hematopoietic Continuum 14
From static risk to dynamic disease monitoring: the role of MRD and immune profiling in multiple myeloma 14
To Treat or Not to Treat: Navigating Early‐Stage CLL in the Era of Targeted Therapy 13
Multiple Myeloma and the Illusion of the Evidence Pyramid 11
Minimal residual disease in diffuse large B‐cell lymphoma after first‐line therapy: Defining the continuum from metabolic remission to molecular clearance 11
Mechanisms of post-transplant AML relapse and therapeutic implications 10
When MRD Is Not MRD: A Context-Dependent Interpretation in Clinical Decision-Making: A Context‐Dependent Interpretation in Clinical Decision‐Making 10
Unexplained Anemia of Aging: From Residual Label to Mechanism‐Based Syndrome 10
Ferroptosis in Lymphoproliferative Disorders 9
Bridging Randomized Trial Efficacy and Real‐World Effectiveness in Multiple Myeloma: Integrating Clinical Trials and Real‐World Evidence for Individualized Care 8
Engineering Hematopoietic Immunity: The Next Evolution of Transplantation and Cellular Therapy 7
Totale 2.909
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11.881
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.881
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202242 0 0 0 5 2 1 1 14 1 2 5 11
2022/202391 10 12 3 12 14 5 2 10 14 1 5 3
2023/202494 11 5 8 10 2 17 9 1 5 5 10 11
2024/2025184 11 15 5 11 3 5 5 7 26 24 12 60
2025/20261.630 64 114 227 117 198 123 118 87 158 208 128 88
2026/2027829 159 70 219 381 0 0 0 0 0 0 0 0
Totale 2.909